by Lisa Chamoff
, Contributing Reporter | July 27, 2020
From the July 2020 issue of HealthCare Business News magazine
Densitas densityai breast density assessment software
In February of this year, the company has updated its densitas densityai breast density assessment software, which was first FDA-cleared in 2018, with a deep learning solution. The technology was previously based on handcrafted features and machine learning, and Mo Abdolell, chief executive officer of Densitas, believes the new approach is more aligned with how radiologists visualize breast density in mammograms.
“The algorithm still has the same purpose,” Abdolell said. “It’s still classifying breast density tissue composition according to the ACR BI-RADS 5th Edition density scale, but we use a deep learning approach to build out our algorithm. What it does is learn on its own from the data set without requiring handcrafted features.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
The company has also expanded its densitas qualityai solution, an AI-based evaluation of mammographic image quality with a focus on positioning errors, into a full web-based analytics platform.
The solution is now available both at the point of care and presented in a system-level context, with access to data of all mammograms performed across a health system.
“With AI automation, there’s now a unique capacity to generate deeper insights into system level performance and digitalize reporting workflows,” Abdolell said. “Because you have access to all of this data across a whole health system, you can apply continual quality assurance. If you’re going to deliver quality care, you have to be able to employ embedded analytics to all of your mammograms collectively. You get a bird’s eye view and you get to see what’s going on in your mammography facilities across your health system.”
Fujifilm adds tomosynthesis biopsy option to ASPIRE Cristalle mammo system
Last year, Fujifilm announced that three new image processing and software advancements for its ASPIRE Cristalle digital mammography system – S-View, Iterative Super-resolution Reconstruction (ISR), and Tomosynthesis Spot — had been FDA-cleared.
“The technology allows us to provide a better view in synthetic 2D images with almost 50% less dose, compared to regular 2D plus tomosynthesis,” said Rick Banner, senior director of marketing for FUJIFILM Medical Systems U.S.A. Inc.
In July of 2019, the company also debuted a tomosynthesis biopsy option for the ASPIRE Cristalle, which provides guidance to calculate 3D coordinates of a suspicious lesion in the breast, in addition to the traditional stereotactic method. The option is designed to provide a more efficient workflow that reduces the exam time.
“We want to make sure radiologists are able to provide this option to target lesions that were previously undetectable on tomo biopsy,” Banner said.
The novel coronavirus pandemic has also changed how companies provide service and train customers on its equipment. GE Healthcare has been continuously improving capabilities of its OnWatch preventive maintenance software, and has been piloting a virtual online trainer for mammographers.
“Our goal is to help our customers with this tremendous backlog they will be facing,” said Agnes Berzsenyi, president and chief executive officer of women’s health for GE Healthcare.
Last year, GE Healthcare and healthcare improvement company Premier Inc. announced they would be collaborating to develop a model for a same-day breast cancer diagnosis and treatment model, with streamlined screening and same-day biopsies.
“With our Pristina Serena, we can transform a screening room to an interventional suite in a few minutes,” Berzsenyi said.